“Patients in the FSGS trial and for a diabetic kidney disease study also using DMX-200 have already been allowed by the Australia drug regulator to stay on the treatment through the Special Access Scheme, demonstrating some physician confidence in its benefit to patients. “ * from above article.
There lies the answer to the question re: which trial participants got special access for ongoing treatment- I.e. BOTH!
Ann: Quarterly Appendix 4C and Activities Report, page-186
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.015(3.70%) |
Mkt cap ! $214.7M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 37.0¢ | $2.682M | 6.983M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2585 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 52718 | 3 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |